ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 605

Increased Incidence of Herpes Zoster Among Patients with Systemic Lupus Erythematosus

Eliza F. Chakarvarty1, Kaleb Michaud2, Robert S. Katz3 and Frederick Wolfe4, 1Arthritis and Clinical Immunology, Oklahoma Medical Research Foundation, Oklahoma City, CA, 2Rheumatology, National Data Bank for Rheumatic Diseases & University of Nebraska Medical Center, Omaha, NE, 3Rush University Medical Center, Chicago, IL, 4National Data Bank for Rheumatic Diseases, Wichita, KS

Meeting: 2012 ACR/ARHP Annual Meeting

Keywords: Infection, risk assessment, Systemic lupus erythematosus (SLE), vaccines and viruses

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Title: Systemic Lupus Erythematosus: Clinical Aspects

Session Type: Abstract Submissions (ACR)

 

Background/Purpose:   Herpes zoster (HZ) is the painful reactivation of latent varicella zoster virus infection.  The incidence of HZ may be increased in some autoimmune diseases including systemic lupus erythematosus (SLE).  We examined the incidence and risk factors for HZ in a prospective cohort of patients with physician-diagnosed SLE compared to those diagnosed with non-inflammatory musculoskeletal conditions (MSK). 

Methods: Study subjects were participants in the National Data Bank for Rheumatic Diseases (NDB) longitudinal study of rheumatic disease outcomes.  Participants are followed prospectively with semi-annual detailed questionnaires collecting data on medication use, comorbid conditions, infections (including specific questions on HZ), hospitalizations, and standard patient reported outcomes.  After excluding 808 participants with a history of prior HZ at enrollment, we followed 1,485 SLE patients and 2,775 MSK for incident HZ between 2001 and 2010.  Reports of HZ were validated by confirmation of a physician diagnosis.  Age adjusted incidence rates were calculated for each group.  Cox proportional hazard regression models were used to identify predictors of HZ for the entire cohort as well as for specific predictors for SLE patients.  Zostavax vaccination rates for individuals ≥ 60 years old were compared between groups.

Results:   SLE patients were younger than MSK (48.3 vs. 64.9 years), but had a similar disease duration of 13-14 years at enrollment.  Health Assessment questionnaire at baseline was similar between groups (0.90 SLE vs. 0.87 MSK), although 25% of SLE patients were disabled from work compared to 9% of MSK.  SLE patients had increased incidence of HZ at all ages, with an age-adjusted incidence of 12.0/1000 person-years compared to MSK (8.7/1000 person-years) and a hazard ratio of 1.7 (95% CI 1.08-2.71) for SLE (Figure). Increasing age (HR 1.01, 95%CI 1.00-1.02 per year) and increased HAQ (HR 1.26, 95% CI 1.10-1.44) were independent predictors of HZ.  Among SLE patients, prednisone (HR 2.29, 95% CI 1.24-4.23) and mycophenolate mofetil (HR 5.00, 95% CI 1.40-17.6) conferred additional risk.  SLE had the lowest HZ vaccination rates among age-eligible subjects; 7.1% SLE vs. 13% MSK, p<0.001.

Conclusion:   The incidence of HZ is increased in SLE at all ages when compared to MSK, while vaccination rates remain low.   Prednisone and mycophenolate mofetil are associated with increased risk.

Figure:  Sex-adjusted relative incidence of incident herpes zoster by age for each diagnosis

Description: C:UserschakravartyeAppDataLocalMicrosoftWindowsTemporary Internet FilesContent.Outlook35NOR6T8znowgroups.tif


Disclosure:

E. F. Chakarvarty,
None;

K. Michaud,
None;

R. S. Katz,
None;

F. Wolfe,
None.

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to 2012 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/increased-incidence-of-herpes-zoster-among-patients-with-systemic-lupus-erythematosus/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology